Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit.Hi. My name is Kathrin LaFaver. I'm a neurologist in Saratoga Springs, New York. I'll be talking on behalf of Medscape today with Dr Meredith Wicklund, who is a senior associate consultant and behavioral neurologist specialist at Mayo Clinic in Arizona. Welcome, Meredith.
— which has really been a hot topic, especially this year with the FDA approval of lecanemab — and associated questions. Could you give us a brief overview of why there has been so much research interest in this topic of anti-amyloid antibodies?The pathologic component of what defines something as Alzheimer's disease is, by definition, presence of amyloid plaques and tau tangles. When it was first discovered in the 1980s that the component of the plaques was actually the amyloid protein — beta amyloid specifically — interest went right from there to developing therapies to directly target the pathology that is Alzheimer's diseas
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TODAYshow - 🏆 389. / 55 Read more »
Source: AKNewsNow - 🏆 460. / 53 Read more »
Source: wjxt4 - 🏆 246. / 63 Read more »